Osang Healthcare Co.,Ltd (KOSDAQ:036220)
9,230.00
+100.00 (1.10%)
Apr 29, 2026, 3:30 PM KST
Osang Healthcare Co.,Ltd Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Other Revenue | -0 | - | - | - | -0 | Upgrade
|
| Revenue | 128,629 | 80,488 | 355,847 | 193,893 | 132,327 | Upgrade
|
| Revenue Growth (YoY) | 59.81% | -77.38% | 83.53% | 46.53% | -48.70% | Upgrade
|
| Cost of Revenue | 71,484 | 54,918 | 134,739 | 95,860 | 84,710 | Upgrade
|
| Gross Profit | 57,145 | 25,570 | 221,108 | 98,033 | 47,617 | Upgrade
|
| Selling, General & Admin | 32,370 | 27,161 | 56,067 | 32,776 | 22,372 | Upgrade
|
| Research & Development | 19,240 | 20,336 | 16,638 | 12,107 | 9,281 | Upgrade
|
| Amortization of Goodwill & Intangibles | 216.07 | 214.2 | 178.57 | 218.32 | 238.9 | Upgrade
|
| Other Operating Expenses | 1,671 | 1,152 | 904.7 | 737.64 | 638.45 | Upgrade
|
| Operating Expenses | 54,718 | 50,136 | 78,768 | 48,778 | 54,724 | Upgrade
|
| Operating Income | 2,427 | -24,566 | 142,339 | 49,255 | -7,106 | Upgrade
|
| Interest Expense | -1,109 | -27.17 | -58.94 | -25.13 | -15.38 | Upgrade
|
| Interest & Investment Income | 687.24 | 1,600 | 3,397 | 677.49 | 831.5 | Upgrade
|
| Earnings From Equity Investments | 652.65 | -2,791 | 925.89 | 259.8 | 913.21 | Upgrade
|
| Currency Exchange Gain (Loss) | -444.17 | 2,672 | 7,649 | 2,132 | 4,054 | Upgrade
|
| Other Non Operating Income (Expenses) | 427.46 | 125.58 | -62.34 | 309.81 | 35.31 | Upgrade
|
| EBT Excluding Unusual Items | 2,641 | -22,987 | 154,190 | 52,609 | -1,287 | Upgrade
|
| Gain (Loss) on Sale of Investments | -75.35 | -56.54 | -104.99 | -984.88 | 1,321 | Upgrade
|
| Gain (Loss) on Sale of Assets | 55.6 | 6.69 | -1,640 | 216.07 | 5.33 | Upgrade
|
| Asset Writedown | -91.39 | -18.43 | -9.69 | -0.07 | -0.68 | Upgrade
|
| Pretax Income | 2,530 | -23,055 | 152,435 | 51,840 | 38.06 | Upgrade
|
| Income Tax Expense | -576.77 | -11,664 | 35,770 | 11,179 | -1,435 | Upgrade
|
| Earnings From Continuing Operations | 3,107 | -11,391 | 116,665 | 40,661 | 1,473 | Upgrade
|
| Minority Interest in Earnings | 2.35 | 26.76 | -228.91 | -13.83 | -12.71 | Upgrade
|
| Net Income | 3,109 | -11,364 | 116,436 | 40,647 | 1,460 | Upgrade
|
| Net Income to Common | 3,109 | -11,364 | 116,436 | 40,647 | 1,460 | Upgrade
|
| Net Income Growth | - | - | 186.46% | 2683.22% | -98.83% | Upgrade
|
| Shares Outstanding (Basic) | 14 | 14 | 13 | 13 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 14 | 14 | 13 | 13 | 12 | Upgrade
|
| Shares Change (YoY) | 1.32% | 4.03% | 1.69% | 4.37% | -7.21% | Upgrade
|
| EPS (Basic) | 226.00 | -837.00 | 9148.50 | 3244.90 | 118.75 | Upgrade
|
| EPS (Diluted) | 226.00 | -837.00 | 8921.00 | 3168.00 | 118.75 | Upgrade
|
| EPS Growth | - | - | 181.60% | 2567.89% | -98.76% | Upgrade
|
| Free Cash Flow | -9,881 | -66,577 | 116,893 | 30,651 | 1,768 | Upgrade
|
| Free Cash Flow Per Share | -718.31 | -4903.48 | 8955.92 | 2387.99 | 143.73 | Upgrade
|
| Gross Margin | 44.43% | 31.77% | 62.14% | 50.56% | 35.98% | Upgrade
|
| Operating Margin | 1.89% | -30.52% | 40.00% | 25.40% | -5.37% | Upgrade
|
| Profit Margin | 2.42% | -14.12% | 32.72% | 20.96% | 1.10% | Upgrade
|
| Free Cash Flow Margin | -7.68% | -82.72% | 32.85% | 15.81% | 1.34% | Upgrade
|
| EBITDA | 10,293 | -17,410 | 148,675 | 54,668 | -3,150 | Upgrade
|
| EBITDA Margin | 8.00% | -21.63% | 41.78% | 28.19% | -2.38% | Upgrade
|
| D&A For EBITDA | 7,866 | 7,156 | 6,335 | 5,413 | 3,956 | Upgrade
|
| EBIT | 2,427 | -24,566 | 142,339 | 49,255 | -7,106 | Upgrade
|
| EBIT Margin | 1.89% | -30.52% | 40.00% | 25.40% | -5.37% | Upgrade
|
| Effective Tax Rate | - | - | 23.47% | 21.57% | - | Upgrade
|
| Advertising Expenses | 263.11 | 246.94 | 309.9 | 325.43 | 332.29 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.